October 25 2022 - 09:00AM
Business Wire
Alert
Share On Facebook
– Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner –
– Additional models of fibrotic diseases including AKI, CKD, NASH, and Myocarditis to commence in Q4 2022 –
– Phase 1 clinical study planned for 1H 2023 –
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner in the medium and high dose groups (21.7% reduction (p <0.05) and 29.3% (p < 0.05), respectively) and was comparable to a known TGF-ß inhibitor of fibrosis used as a positive control (38.1% reduction (P < 0.05)).
“These promising preclinical results offer hope of new prophylactic option for preventing the deleterious effects of AKI following multiple types of surgery,” said Lakhmir Chawla, M.D. at the Jennifer Moreno Department of Veterans Affairs Medical Center, San Diego, CA, and a leading expert in AKI, “as well as potential new treatment options for active acute kidney injury and chronic kidney disease. I look forward to collaborating with Revelation as REVTx-300 moves through the development process.”
The unilateral ureteral obstruction (UUO) model is appropriate for studying the anti-inflammatory and anti-fibrotic effects of potential new therapies for acute and chronic kidney disease as complete ureteral obstruction of one kidney results in significant inflammation and subsequent fibrosis of the affected kidney over a 7-day period.
The present study consisted of 6 groups with the following outcomes on renal cortical fibrosis as measured by detection of collagen deposition using picosirius red stained histology sections assessed at three different sampling depths.
Group 1 animals had no UUO surgery and received vehicle only (collagen deposition: 2.36 ± 0.44%).
Group 2 animals had UUO surgery and received vehicle only (collagen deposition: 2.36 ± 0.44%).
Group 3 animals had UUO surgery and received SB-525334, a known TGF-ß inhibitor of fibrosis (collagen deposition: 3.02 ± 0.37%, 38.1% reduction vs Group 2, p < 0.05).
Group 4 animals had UUO surgery and received 0.1 mg/kg REVTx-300 (collagen deposition: 4.96 ± 0.95 %, 0% reduction vs Group 2).
Group 5 animals had UUO surgery and received 0.3 mg/kg REVTx-300 (collagen deposition: 3.82 ± 0.91%, 21.7% reduction vs Group 2, p < 0.05).
Group 6 animals had UUO surgery and received 0.9 mg/kg REVTx-300 (collagen deposition: 3.45 ± 0.54%, 29.3% reduction vs Group 2, p < 0.05).
Revelation will continue evaluating the potential of REVTx-300 in additional preclinical models including CKD, nonalcoholic steatohepatitis (NASH), and myocarditis to identify optimal dosing conditions required for prevention and resolution of inflammation and fibrosis. Revelation plans to initiate Phase 1 clinical studies in the first half of 2023.
“This preclinical data along with observations from our previous clinical studies support the validity and promise of our PHAD-based programs to beneficially modulate the inflammatory process,” said James Rolke, Chief Executive Officer of Revelation. “With the increased prevalence of inflammation-mediated diseases, we remain focused on leveraging PHAD-specific stimulation of TLR4 to discover therapies to provide relief from conditions including AKI, CKD, myocarditis, and NASH.”
About REVTx-300
REVTx-300 is our proprietary formulation for systemic administration of PHAD and is being developed as a potential therapy for the treatment of acute and chronic organ disease including chronic kidney disease (CKD, acute kidney injury (AKI), myocarditis, and nonalcoholic steatohepatitis (NASH). Chronic disease of an organ, due to chronic inflammation and subsequent fibrosis, follows a pattern of perpetual and ongoing destruction of living functional cells and subsequent replacement by the non-functional protein, collagen, resulting in fibrosis (scar tissue) (Wilson). The establishment of fibrosis and subsequent death of the organ is driven by ongoing inflammatory processes and reactive oxygen species associated with the innate immune response. We believe redirection of the innate immune response with REVTx-300 from a pro-inflammatory state to an anti-inflammatory (protective) state may rebalance the innate immune response to slow down or halt the progressive destruction and scarring of organ tissue, allowing the healing process to take place.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx-100 is being developed as a prevention and treatment of infection. REVTx-200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, AKI, myocarditis, and NASH. REVTx-99b is being developed as a treatment for food allergies. REVDx-501 is being develope
Recent REVB News
- Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 • Business Wire • 05/10/2024 08:52:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 • Business Wire • 03/22/2024 08:15:00 PM
- Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 03/13/2024 01:00:00 PM
- Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference • Business Wire • 03/12/2024 01:00:00 PM
- Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini • Business Wire • 03/04/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:05 AM
- Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 02/13/2024 02:00:00 PM
- Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 03:19:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:01:23 PM
- Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering • Business Wire • 02/05/2024 09:41:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2024 09:06:10 PM
- Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering • Business Wire • 02/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:21:32 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/30/2024 08:32:42 PM
- Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 01/30/2024 02:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/29/2024 10:32:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:18:01 PM
- Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024 • Business Wire • 01/23/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/22/2023 10:06:53 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 06:23:34 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/12/2023 09:59:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:30:16 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 • Business Wire • 11/13/2023 09:05:00 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM